chrX-154535996-A-G
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM5PP3_StrongPP5_Very_Strong
The ENST00000393562.10(G6PD):āc.208T>Cā(p.Tyr70His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000546 in 1,098,064 control chromosomes in the GnomAD database, including 1 homozygotes. There are 3 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y70C) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000393562.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
G6PD | NM_001360016.2 | c.208T>C | p.Tyr70His | missense_variant | 4/13 | ENST00000393562.10 | NP_001346945.1 | |
G6PD | NM_000402.4 | c.298T>C | p.Tyr100His | missense_variant | 4/13 | NP_000393.4 | ||
G6PD | NM_001042351.3 | c.208T>C | p.Tyr70His | missense_variant | 4/13 | NP_001035810.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
G6PD | ENST00000393562.10 | c.208T>C | p.Tyr70His | missense_variant | 4/13 | 1 | NM_001360016.2 | ENSP00000377192 | P4 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD3 exomes AF: 0.0000218 AC: 4AN: 183344Hom.: 1 AF XY: 0.0000147 AC XY: 1AN XY: 67828
GnomAD4 exome AF: 0.00000546 AC: 6AN: 1098064Hom.: 1 Cov.: 31 AF XY: 0.00000825 AC XY: 3AN XY: 363428
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:4
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Aug 04, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 10, 2022 | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 70 of the G6PD protein (p.Tyr70His). This variant is present in population databases (rs137852349, gnomAD 0.02%). This missense change has been observed in individual(s) with G6PD-related conditions (PMID: 7825590, 17233850, 33069889). ClinVar contains an entry for this variant (Variation ID: 10416). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt G6PD protein function. This variant disrupts the p.Tyr70 amino acid residue in G6PD. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7577654, 20621077, 21446359; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | curation | Dunham Lab, University of Washington | Aug 12, 2022 | Variant found in unrelated hemizygotes with deficiency and anemia (PS4_M, PP4). Decreased activity in red blood cells (4-33%) (PS3). Predicted to be damaging by SIFT and PolyPhen (PP3). Below expected carrier frequency in gnomAD (PM2). Post_P 0.994 (odds of pathogenicity 1517, Prior_P 0.1). - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Lifecell International Pvt. Ltd | - | This variant in exon 4 of the G6PD gene results in the amino acid substitution from Tyrosine to Histidine at codon 100 (p.Tyr100His) with the sequence change of c.298T>C (NM_000402.4). This variant was observed in a proband with decreased level of G6PD enzyme (<2.4 U/dL) which was screened for advanced newborn screening with confirmatory genetic reflex testing at Lifecell diagnostics. There is a moderate physicochemical difference between Tyrosine and Histidine. The observed variant is not present in both the 1000 Genomes and gnomAD databases. The reference base is conserved across the species and in-silico predictions by Polyphen and SIFT are damaging. This variant lies in the Glucose-6-phosphate dehydrogenase, NAD binding domain of the Glucose-6-phosphate 1-dehydrogenase protein (http://pfam.xfam.org/family/G6PD_N). This is a Class II variant associated with moderate G6PD deficiency (<10% activity), with intermittent hemolysis. This variant is also known as G6PD Namoru in the literature. This variant has previously been reported for Glucose-6- phosphate dehydrogenase (G6PD) deficiency by Arunachalam AK et al., 2019 and Chalvam R., et al. 2007; PMID: 17233850, Ganczakowski M et al. 1995; PMID: 7825590. - |
G6PD NAMORU Other:1
other, no assertion criteria provided | literature only | OMIM | Jul 28, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at